XML 72 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Financial Liabilities - 2027 Term Loan - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 01, 2024
Feb. 05, 2024
Apr. 30, 2024
Jun. 30, 2024
Jun. 30, 2024
Debt Instrument [Line Items]          
Interest rate         13.30%
Debt partial prepayment to be Made   $ 175,000      
Minimum net sales convenant level agreed to be maintained over past year   $ 125,000      
Outstanding amount paid off         $ 260,387
Loss on debt extinguishment       $ 12,630 $ 12,630
2027 Term Loans          
Debt Instrument [Line Items]          
Principal amount $ 250,000   $ 250,000    
Interest rate         0.26161%
Spread on variable rate         1.00%
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]         us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember
Partial prepayment of principal $ 175,000        
Outstanding amount paid off     $ 175,000    
2027 Term Loans | BioPharma Credit Investments V GP LLC          
Debt Instrument [Line Items]          
Principal amount       300,000 $ 300,000
Funded amount       $ 250,000 250,000
Outstanding amount paid off         $ 79,600
Prepayment premium percentage       3.00% 3.00%
Loss on debt extinguishment       $ 12,600 $ 12,600
2027 Term Loans | Starting April 1, 2023 | BioPharma Credit Investments V GP LLC          
Debt Instrument [Line Items]          
Stated interest rate       8.25% 8.25%